ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,607.01
-0.45%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Anixa Biosciences Inc (ANIX)

  7. Anixa Biosciences Inc (ANIX) News

Anixa Biosciences (ANIX)

Anixa Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANIX
DateTimeSourceHeadlineSymbolCompany
30/04/202412:45PR Newswire (US)Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024NASDAQ:ANIXAnixa Biosciences Inc
18/04/202413:20PR Newswire (US)Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory BoardNASDAQ:ANIXAnixa Biosciences Inc
14/03/202412:45PR Newswire (US)Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested PartiesNASDAQ:ANIXAnixa Biosciences Inc
11/03/202412:00PR Newswire (US)Anixa Biosciences Announces Presentation at 24th Annual World Vaccine CongressNASDAQ:ANIXAnixa Biosciences Inc
12/02/202412:30PR Newswire (US)Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical TrialNASDAQ:ANIXAnixa Biosciences Inc
08/02/202421:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ANIXAnixa Biosciences Inc
29/01/202413:50PR Newswire (US)Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology ConferenceNASDAQ:ANIXAnixa Biosciences Inc
23/01/202412:55PR Newswire (US)Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine TechnologyNASDAQ:ANIXAnixa Biosciences Inc
17/01/202400:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
17/01/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
17/01/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
17/01/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
17/01/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
16/01/202422:29Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ANIXAnixa Biosciences Inc
16/01/202421:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANIXAnixa Biosciences Inc
16/01/202421:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANIXAnixa Biosciences Inc
10/01/202414:00PR Newswire (US)Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024NASDAQ:ANIXAnixa Biosciences Inc
14/12/202312:15PR Newswire (US)Anixa Biosciences to Present at Biotech Showcase 2024NASDAQ:ANIXAnixa Biosciences Inc
07/12/202311:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANIXAnixa Biosciences Inc
06/12/202323:00PR Newswire (US)Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer VaccineNASDAQ:ANIXAnixa Biosciences Inc
06/12/202321:05PR Newswire (US)Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer VaccineNASDAQ:ANIXAnixa Biosciences Inc
27/11/202313:30PR Newswire (US)Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine TechnologyNASDAQ:ANIXAnixa Biosciences Inc
02/11/202314:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
31/10/202312:30PR Newswire (US)Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National ConferenceNASDAQ:ANIXAnixa Biosciences Inc
23/10/202313:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:ANIXAnixa Biosciences Inc
13/10/202313:30PR Newswire (US)Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical TrialNASDAQ:ANIXAnixa Biosciences Inc
11/10/202315:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANIXAnixa Biosciences Inc
03/10/202313:30PR Newswire (US)Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine TechnologyNASDAQ:ANIXAnixa Biosciences Inc
19/09/202313:30PR Newswire (US)Anixa Biosciences Establishes Cancer Business Advisory BoardNASDAQ:ANIXAnixa Biosciences Inc
06/09/202321:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANIXAnixa Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:ANIX

Your Recent History

LSE
AGL
Angle
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
LSE
SRSP
Sirius Petroleum
LSE
POS
Plexus
LSE
AAU
Ariana Resources
LSE
LLOY
Lloyds Banking
LSE
BT.A
Bt
LSE
BIRD
Blackbird
LSE
INSG
Insig Ai
LSE
TERN
Tern
LSE
APTA
Aptamer
LSE
THUS
Thus
LSE
MIN
Minoan
LSE
I3E
I3 Energy
LSE
IES
Invinity Energy Systems
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved